The notion “hepatitis” means inflammation of the liver or its cells, often caused by some virus and accompanied in its initial phase to by symptoms similar to flu: fever, loss of appetite, muscle/joint aches, etc. According to the virus type hepatitis is divided into several types: hepatitis A, В C, D and E. Hepatitis can disappear on its own, but in some cases it can lead to serious liver dysfunctions and severe complications such as fibrosis, liver failure or cancer, cryoglobulinemia, an a lot more.
The world hepatitis drugs market has experienced stable growth over the recent years, driven by the constant increase of demand from developed countries, introduction of new products and technological advancement in the medical industry. It is set to continue growing at a CARG of above 12% through 2015. Gilead Sciences, Merck & Co., GlaxoSmithKline, Bristol-Myers Squibb and Hoffmann-La Roche are amid the key hepatitis market players.
The collection of the research reports found in this catalogue provides an extensive insight into the hepatitis market at different geographical scales. Relevant information on the market size, share, segmentation as well as major factors influencing the market is presented in the researches. The reports offer detailed assessment of the competitive landscape and profile top companies. In addition, discussions of future market prospects for the are at hand in the research reports.
Publications found:
152
Sort by:
2015 Strategies in the European Hepatitis Diagnostic Testing Market
US$ 5,520.00
... report presents a detailed analysis of the Hepatitis diagnostics market in Europe, (France, Germany, Italy, Spain, UK). Current scientific views on the ... and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning ...
May 2015
295 pages
2015 Strategies in the French Hepatitis Diagnostic Testing Market
US$ 3,120.00
... report presents a detailed analysis of the Hepatitis diagnostics market in France. Current scientific views on the Hepatitis definition, epidemiology and ... and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning ...
May 2015
241 pages
2015 Strategies in the German Hepatitis Diagnostic Testing Market
US$ 3,120.00
... report presents a detailed analysis of the Hepatitis diagnostics market in Germany. Current scientific views on the Hepatitis definition, epidemiology and ... identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning ...
May 2015
241 pages
2015 Strategies in the Italian Hepatitis Diagnostic Testing Market
US$ 3,120.00
... report presents a detailed analysis of the Hepatitis diagnostics market in Italy. Current scientific views on the Hepatitis definition, epidemiology and ... and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning ...
May 2015
241 pages
2015 Strategies in the Japanese Hepatitis Diagnostic Testing Market
US$ 3,120.00
... report presents a detailed analysis of the Hepatitis diagnostics market in Japan. Current scientific views on the Hepatitis definition, epidemiology and ... and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning ...
May 2015
241 pages
2015 Strategies in the Spanish Hepatitis Diagnostic Testing Market
US$ 3,120.00
... report presents a detailed analysis of the Hepatitis diagnostics market in Spain. Current scientific views on the Hepatitis definition, epidemiology and ... and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning ...
May 2015
241 pages
Competitor Analysis: Nonalcoholic Steatohepatitis (NASH) – Novel Drug Candidates
US$ 260.00
Competitor Analysis: Nonalcoholic Steatohepatitis (NASH) – Novel Drug Candidates The Competitive Intelligence report about Nonalcoholic Steatohepatitis (NASH) - Novel Drug Candidates provides a competitor analysis in the development pipeline of novel therapeutics for treatment of NASH. Purchase of the pdf ...
January 2015
25 pages
2014-2014 Japanese Hepatitis Markers Testing Market: Hospitals, Blood Banks, Commercial Labs--Supplier Shares and Sales Forecasts for 10 Immunodiagnostic and NAT Procedures
US$ 3,120.00
... $3,900. DataPack (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Japan. Current scientific ... , epidemiology and etiology are reviewed. The report provides five-year test volume and sales forecasts for HAV NAT, HBV NAT, ...
November 2014
241 pages
2014-2014 French Hepatitis Markers Testing Market: Hospitals, Blood Banks, Commercial Labs--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures
US$ 3,120.00
... $3,900. DataPack (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in France. Current scientific ... , epidemiology and etiology are reviewed. The report provides five-year test volume and sales forecasts for HAV NAT, HBV NAT, ...
November 2014
241 pages
2014-2014 German Hepatitis Markers Testing Market: Hospitals, Blood Banks, Commercial Labs--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures
US$ 3,120.00
... $3,900. DataPack (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Germany. Current scientific ... , epidemiology and etiology are reviewed. The report provides five-year test volume and sales forecasts for HAV NAT, HBV NAT, ...
November 2014
241 pages
2014-2014 Italian Hepatitis Markers Testing Market: Hospitals, Blood Banks, Commercial Labs--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures
US$ 3,120.00
... $3,900. DataPack (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Italy. Current scientific ... , epidemiology and etiology are reviewed. The report provides five-year test volume and sales forecasts for HAV NAT, HBV NAT, ...
November 2014
241 pages
2014-2014 Spanish Hepatitis Markers Testing Market: Hospitals, Blood Banks, Commercial Labs--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures
US$ 3,120.00
... $3,900. DataPack (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Spain. Current scientific ... , epidemiology and etiology are reviewed. The report provides five-year test volume and sales forecasts for HAV NAT, HBV NAT, ...
November 2014
241 pages
2014-2018 World Hepatitis Markers Testing Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies, Opportunities for Suppliers--France, Germany, Italy, Japan, Spain, UK, US
US$ 7,600.00
... (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides the ... report presents sales and market share estimates for major suppliers of Hepatitis tests. Also, the report examines the market applications of DNA ...
November 2014
320 pages
2014-2018 European Hepatitis Markers Testing Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures
US$ 5,520.00
... , supplier shares) $4,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Europe, (France, Germany, Italy, Spain, UK). Current scientific ... presents sales and market share estimates for major suppliers of Hepatitis tests. Also, the report examines the market applications of DNA ...
November 2014
295 pages
Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight
US$ 7,495.00
... represents a paradigm shift compared to the protease inhibitors and interferon regimens. With convenient, efficacious and safer therapies coming through the ... will shape the future market. Key Benefits Therapy Trends: Hepatitis C -- Game changing regimens to revolutionise treatment landscape examines the most prominent insights gained ...
March 2014
163 pages
European Hepatitis Diagnostics Market 2014: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures
US$ 5,520.00
... , supplier shares) $4,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Europe, (France, Germany, Italy, Spain, UK). Current scientific views on the ... , HBV NAT, HBs Ag, HCV, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed in the ...
January 2014
295 pages
US Hepatitis Diagnostics Market 2014: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures
US$ 3,120.00
... , sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in the US. Current scientific views on the ... HBV NAT , HBs Ag, HCV , Anti-HBc , Anti-HBs , Anti-HAV , Hepatitis Delta , HBc Ag , HBe Ag , and ALT/SGPT tests performed in the ...
January 2014
241 pages
2014 Opportunities in the US Hepatitis Diagnostic Testing Market
US$ 3,120.00
... analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns. Contains 241 ...
December 2013
241 pages
Physician Views: Entering the post-interferon era – will Gilead Sciences dominate hepatitis C?
US$ 695.00
... currently anticipated for AbbVie. To gain a better perspective on how physicians expect to use interferon-free regimens, FirstWord is polling gastroenterologists/hepatologists and infectious ... of genotype 1 patients they would prescribe an interferon-sparing, once-daily, single-tablet therapy rather than an interferon-sparing multi-tablet therapy dosed ...
November 2013
2014 Analysis of the US Hepatitis Diagnostics Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices - Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures
US$ 3,120.00
Complete report $3,900. DataPack (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in the US. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test ...
November 2013
241 pages
2014 Analysis of the European Hepatitis Diagnostics Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices - Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures
US$ 5,520.00
Complete report $6,900. DataPack (test volumes, sales forecasts, supplier shares) $4,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Europe, (France, Germany, Italy, Spain, UK). Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. ...
November 2013
295 pages
Therapy Class Overview : Hepatitis C Virus Infection
US$ 1,000.00
... Oral IFN –Free combinations for Treatment of HCV and ROW opportunity Competitive Landscape - IFN-Free drugs HCV Vaccines and their progress Difficult to treat and drugs for HCV-HIV co infection Market ...
October 2013
33 pages
Hepatitis C Drug Pipeline Analysis
US$ 1,800.00
... when purchasing Hard Copy License depending on the location. “Hepatitis C Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ... C. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, ...
August 2013
700 pages
Hepatitis Drugs and Vaccines: World Market 2013-2023
US$ 2,635.00
... . What prospects for regions and countries? Developments worldwide expand the hepatitis products market, especially rising demand for medicines in emerging countries. ... you possibilities, helping you stay ahead. Nine ways Hepatitis Drugs and Vaccines: World Market 2013-2023 helps you To sum up, our ...
June 2013
197 pages
Therapy Trends Consensus Outlook: Hepatitis C
US$ 4,995.00
... introduction more effective and tolerable pipeline agents. Therapy Trends Consensus Outlook: Hepatitis C analyses the global HCV market players and ... results to in-depth discussions with leading key opinion leaders (KOLs). Consensus forecasts also act as an excellent benchmark against which other projections ...
November 2012
KOL Insight: Hepatitis C: the Race for the First Interferon-free Regimen
US$ 7,495.00
... with the greatest insight into how HCV clinical research will shape the future market. Key Benefits Hepatitis C: the race for the first interferon-free regimen examines the most prominent insights gained from the ... generation protease inhibitors Develop planning strategies based on insight from the field’s foremost KOLs Identify the unmet needs and opportunities for ...
October 2012
246 pages
Global Hepatitis Testing Market, 2010-2018 (DataPack)
US$ 5,520.00
... US, Europe (France, Germany, Italy, Spain, UK) and Japan. The report provides the 2010-2018 test volume and sales forecasts for HAV NAT, HBV NAT, HBs Ag, HCV ... in addition to test volume and sales projections, the report presents the 2010 sales and market share estimates for major suppliers of Hepatitis tests.
July 2012
Global Hepatitis C Virus (HCV) Market - An Analysis
US$ 800.00
... come due to increase in number of HCV positive drug addicts. This report titled “Global Hepatitis C Virus (HCV) Market– An Analysis” analyzes the various ... types, stages and incidences of HCV in different geographies. ...
August 2011
47 pages
Competitor Analysis: Targeted Therapy of Hepatitis C
US$ 826.00
Product description The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2011. Purchase of the downloadable pdf report includes a 6-month online ...
August 2011
91 pages
Hepatitis B Therapy Area Pipeline Report
US$ 1,495.00
Life Science Analytics', Hepatitis B Therapy Area Pipeline Report contains detailed information on the hepatitis b drug pipeline. This report provides insight into the pipeline status of hepatitis b d...
September 2010
344 pages
Hepatitis C Therapy Area Pipeline Report
US$ 1,495.00
Life Science Analytics', Hepatitis C Therapy Area Pipeline Report contains detailed information on the hepatitis c drug pipeline. This report provides insight into the pipeline status of hepatitis c d...
September 2010
881 pages
Hepatitis Therapy Area Pipeline Report
US$ 1,495.00
Life Science Analytics', Hepatitis Therapy Area Pipeline Report contains detailed information on the hepatitis drug pipeline. This report provides insight into the pipeline status of hepatitis drugs b...
September 2010
68 pages
Infections Hepatitis B Therapy Area Pipeline Report
US$ 1,495.00
Life Science Analytics', Hepatitis B Therapy Area Pipeline Report contains detailed information on the hepatitis b drug pipeline. This report provides insight into the pipeline status of hepatitis b d...
January 2010
332 pages
Infections Hepatitis C Therapy Area Pipeline Report
US$ 1,495.00
Life Science Analytics', Hepatitis C Therapy Area Pipeline Report contains detailed information on the hepatitis c drug pipeline. This report provides insight into the pipeline status of hepatitis c d...
January 2010
888 pages
